1
|
Ao H, Song H, Li J, Wang X. Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2. Drug Deliv 2024; 31:2324716. [PMID: 38555735 PMCID: PMC10984232 DOI: 10.1080/10717544.2024.2324716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 02/14/2024] [Indexed: 04/02/2024] Open
Abstract
Annonaceous acetogenins (ACGs) have potent anti-tumor activity, and the problems of their low solubility, hemolysis, and in vivo delivery have been solved by encapsulation into nanoparticles. However, the high toxicity still limits their application in clinic. In this paper, the co-delivery strategy was tried to enhance the in vivo anti-tumor efficacy and reduce the toxic effects of ACGs. Ginsenoside Rh2, a naturally derived biologically active compound, which was reported to have synergistic effect with paclitaxel, was selected to co-deliver with ACGs. And due to its similarity with cholesterol in chemical structure, the co-loading liposomes, (ACGs + Rh2)-Lipo, were successfully constructed using Rh2 instead of cholesterol as the membrane material. The obtained (ACGs + Rh2)-Lipo and ACGs-Lipo had similar mean particle size (about 80 nm), similar encapsulation efficiency (EE, about 97%) and good stability. The MTS assay indicated that (ACGs + Rh2)-Lipo had stronger toxicity in vitro. In the in vivo study, in contrast to ACGs-Lipo, (ACGs + Rh2)-Lipo demonstrated an improved tumor targetability (3.3-fold in relative tumor targeting index) and significantly enhanced the antitumor efficacy (tumor inhibition rate, 72.9 ± 5.4% vs. 60.5 ± 5.4%, p < .05). The body weight change, liver index, and spleen index of tumor-bearing mice showed that Rh2 can attenuate the side effects of ACGs themselves. In conclusion, (ACGs + Rh2)-Lipo not only alleviated the toxicity of ACGs to the organism, but also enhanced their anti-tumor activity, which is expected to break through their bottleneck.
Collapse
Affiliation(s)
- Hui Ao
- Department of Pharmacy, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, PR China
| | - Huizhu Song
- Department of Pharmacy, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, PR China
| | - Jing Li
- Department of Pharmacy, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, PR China
| | - Xiangtao Wang
- Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China
| |
Collapse
|
2
|
Vala RM, Tandon V, Nicely LG, Guo L, Gu Y, Banerjee S, Patel HM. Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and in vitro anti-glioma activity. Ann Med 2022; 54:2549-2561. [PMID: 36120909 PMCID: PMC9683054 DOI: 10.1080/07853890.2022.2123559] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
A series of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles was synthesised and screened for their potential to inhibit kinases and exhibit anticancer activity against primary patient-derived glioblastoma 2D cells and 3D neurospheres. A collection of 10 compounds was evaluated against glioma cell lines, with compound 4j exhibiting promising glioma growth inhibitory properties. Compound 4j was screened against 139 purified kinases and exhibited low micromolar activity against kinase AKT2/PKBβ. AKT signalling is one of the main oncogenic pathways in glioma and is often targeted for novel therapeutics. Indeed, AKT2 levels correlated with glioma malignancy and poorer patient survival. Compound 4j inhibited the 3D neurosphere formation in primary patient-derived glioma stem cells and exhibited potent EC50 against glioblastoma cell lines. Although exhibiting potency against glioma cells, 4j exhibited significantly less cytotoxicity against non-cancerous cells even at fourfold-fivefold the concentration. Herein we establish a novel biochemical kinase inhibitory function for N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles and further report their anti-glioma activity in vitro for the first time.KEY MESSAGEAnti-glioma pyrano[2,3-c]pyrazole 4j inhibited the 3D neurosphere formation in primary patient-derived glioma stem cells. 4j also displayed PKBβ/AKT2 inhibitory activity. 4j is nontoxic towards non-cancerous cells.
Collapse
Affiliation(s)
- Ruturajsinh M Vala
- Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar, India
| | - Vasudha Tandon
- Department of Cellular & Systems Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - Lynden G Nicely
- Department of Cellular & Systems Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - Luxia Guo
- Key Laboratory of Material Chemistry for Energy Conversion and Storage, Ministry of Education, Hubei, Key Laboratory of Material Chemistry and Service Failure, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China
| | - Yanlong Gu
- Key Laboratory of Material Chemistry for Energy Conversion and Storage, Ministry of Education, Hubei, Key Laboratory of Material Chemistry and Service Failure, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China
| | - Sourav Banerjee
- Department of Cellular & Systems Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - Hitendra M Patel
- Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar, India
| |
Collapse
|
3
|
de Vasconcelos A, Boeira AJZ, Drawanz BB, Pedra NS, Bona NP, Stefanello FM, Cunico W. 2,4-Thiazolidinedione as Precursor to the Synthesis of Compounds with Anti-glioma Activities in C6 and GL261 Cells. Med Chem 2021; 17:601-610. [PMID: 32242786 DOI: 10.2174/1573406416666200403075826] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 01/27/2020] [Accepted: 01/29/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Thiazolidinediones (TZDs) represent an important class of heterocyclic compounds that have versatile biological activities, including anticancer activity. Glioma is one of the most common primary brain tumors, and it is responsible for most of the deaths caused by primary brain tumors. In the present work, 2,4-thiazolidinediones were synthesized via a multicomponent microwave one-pot procedure. The cytotoxicity of compounds was analyzed in vitro using rat (C6) and mouse (GL261) glioblastoma cell lines and primary cultures of astrocytes. OBJECTIVE This study aims to synthesize and characterize 2,4-thiazolidinediones and evaluate their antitumor activity. METHODS TZDs were synthesized from three components: 2,4-thiazolidinedione, arene-aldehydes, and aryl chlorides. The reactions were carried out inside a microwave and monitored using thinlayer chromatography (TLC). Compounds were identified and characterized using gas chromatography coupled to mass spectrometry (CG-MS) and hydrogen (1H-NMR) and carbon nuclear magnetic resonance spectroscopy (13C-NMR). The antitumor activity was analyzed using the 3-(4,5- dimethyl)-2,5-diphenyltetrazolium bromide (MTT) reduction test, in which cell viability was verified in the primary cultures of astrocytes and in rat and mouse glioblastoma cells exposed to the synthesized compounds. The cytotoxicity of all derivatives was analyzed at the 100 μM concentration, both in astrocytes and in the mouse and rat glioblastoma cell lines. The compounds that showed the best results, 4CI and 4DI, were also tested at concentrations 25, 50, 100, 175, and 250 μM to obtain the IC50. RESULTS Seventeen TZD derivatives were easily obtained through one-pot reactions in 40 minutes with yields ranging from 12% to 49%. All compounds were cytotoxic to both glioblastoma cell lines without being toxic to the astrocyte primary cell line at 100 μM, thus demonstrating a selective activity. Compounds 4CI and 4DI showed the best results in the C6 cells: IC50 of 28.51 μM and 54.26 μM, respectively. CONCLUSION The compounds were not cytotoxic in astrocyte culture, demonstrating selectivity for malignant cells. Changes in both rings are important for anti-glioma activity in the cell lines tested. TZD 4CI had the best anti-glioma activity.
Collapse
Affiliation(s)
- Alana de Vasconcelos
- Laboratorio de Quimica Aplicada a Bioativos (LaQuiABio), Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| | - Ana Júlia Zulian Boeira
- Laboratorio de Quimica Aplicada a Bioativos (LaQuiABio), Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| | - Bruna Bento Drawanz
- Laboratorio de Quimica Aplicada a Bioativos (LaQuiABio), Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| | - Nathalia Stark Pedra
- Laboratorio de Neuroquimica, inflamacao e Cancer (Neurocan) Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| | - Natália Pontes Bona
- Laboratorio de Neuroquimica, inflamacao e Cancer (Neurocan) Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| | - Francieli Moro Stefanello
- Laboratorio de Neuroquimica, inflamacao e Cancer (Neurocan) Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| | - Wilson Cunico
- Laboratorio de Quimica Aplicada a Bioativos (LaQuiABio), Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitario s/n, Capao do Leao, RS, CEP: 96010-900, Brazil
| |
Collapse
|
4
|
Peng Y, Lu J, Li R, Zhao Y, Hai L, Guo L, Wu Y. Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine. ACS Appl Mater Interfaces 2021; 13:26682-26693. [PMID: 34061501 DOI: 10.1021/acsami.1c02404] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Glioma is one of the most lethal and complex tumors, and thus, an effective drug delivery system must selectively target the tumor sites and release its cargos in a controlled manner. For the first time, we combined chemotherapeutic agent doxorubicin (DOX) and chemosensitizer lonidamine (LND) to synergistically treat glioma. We also designed and prepared multitargeted redox-sensitive liposomes (Lip-SPG) co-modified with glucose and triphenylphosphonium (TPP) to effectively deliver DOX and LND for anti-glioma therapy. The anti-glioma evaluation shows that DOX and LND have a synergistic effect and Lip-SPG could further enhance their cooperation. In vitro, Lip-SPG could increase the cellular uptake and mitochondrial uptake on bEnd.3 cells and C6 cells with multitargeting ability on the brain, tumor, and mitochondria mediated by glucose and TPP. Lip-SPG can also escape from lysosomes before entering the mitochondria. The anti-glioma efficacy in vitro shows that Lip-SPG can inhibit tumor cell proliferation and induce apoptosis. In addition, Lip-SPG have a remarkable interference to mitochondria, such as reducing intracellular ATP production, inducing ROS generation, and promoting mitochondrial membrane potential depolarization. Furthermore, in vivo, the introduction of PEGylation via glutathione-sensitive disulfide bonds endows Lip-SPG with favorable pharmacokinetic properties, brain targeting ability, low toxicity to normal tissues, and great anti-glioma efficacy with the survival time extended from 19 to 39 days. In conclusion, Lip-SPG are an effective delivery system for synergistically treating glioma with DOX and LND.
Collapse
Affiliation(s)
- Yao Peng
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| | - Jiaqi Lu
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| | - Ru Li
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| | - Yi Zhao
- Department of Translational Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Li Hai
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| | - Li Guo
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| | - Yong Wu
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
| |
Collapse
|
5
|
Nascimento RP, Dos Santos BL, da Silva KC, Amaral da Silva VD, de Fátima Costa M, David JM, David JP, Moura-Neto V, Oliveira MDN, Ulrich H, de Faria Lopes GP, Costa SL. Reverted effect of mesenchymal stem cells in glioblastoma treated with agathisflavone and its selective antitumoral effect on cell viability, migration, and differentiation via STAT3. J Cell Physiol 2020; 236:5022-5035. [PMID: 33368262 DOI: 10.1002/jcp.30209] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 11/02/2020] [Accepted: 11/26/2020] [Indexed: 12/17/2022]
Abstract
Glioblastoma is the most lethal tumor of the central nervous system, presenting a very poor prognostic, with a survival around 16 months. The interaction of mesenchymal stem cells and tumor cells has been studied, showing a bias in their role favoring or going against aggressiveness. Natural products such as flavonoids have showed their anticancer properties and the synergic potential with the activation of microenvironment cells to inhibit tumor progression. Agathisflavone is a flavonoid studied in neurodegenerative diseases and cancer. The present study investigated the effect of flavonoid in the viability of heterogeneous glioblastoma (GBM) cells considering a coculture or conditioned medium of mesenchymal stem cells (MSCs) effect, as well as the dose-dependent effect of this flavonoid in tumor migration and differentiation via STAT3. Agathisflavone (3-10 μM) induced dose-dependent toxicity to GL-15 and U373 human GBM cells, since 24 h after treatments. It was not toxic to human MSC but modified the pattern of interaction with GBM cells. Agathisflavone also inhibited migration and increased differentiation of human GBM cells, associated with the reduction on the expression of STAT3. These results demonstrate that the flavonoid agathisflavone had a direct anti-glioma effect. However, could be observed its effect in MSCs response that may have an impact in controlling GBM growth and aggressiveness, an important factor to consider for new therapies.
Collapse
Affiliation(s)
- Ravena P Nascimento
- Department of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Federal University of Bahia, Salvador, Bahia, Brazil.,Post-graduate Program in Biotechnology, State University of de Feira de Santana - UEFS, Feira de Santana, Bahia, Brazil
| | - Balbino L Dos Santos
- Department of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Federal University of Bahia, Salvador, Bahia, Brazil.,Federal University of Vale do São Francisco, Petrolina, Brazil
| | - Karina C da Silva
- Department of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Federal University of Bahia, Salvador, Bahia, Brazil
| | - Victor D Amaral da Silva
- Department of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Federal University of Bahia, Salvador, Bahia, Brazil.,INCT/CNPq-Neurociência Translacional (INNT), Rio de Janeiro, Brazil
| | - Maria de Fátima Costa
- Department of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Federal University of Bahia, Salvador, Bahia, Brazil.,INCT/CNPq-Neurociência Translacional (INNT), Rio de Janeiro, Brazil
| | - Jorge M David
- Department of General and Inorganic Chemistry, Federal University of Bahia, Bahia, Brazil
| | - Juceni P David
- Department of Medication, Faculty of Pharmacy, Federal University of Bahia, Brazil
| | - Vivaldo Moura-Neto
- INCT/CNPq-Neurociência Translacional (INNT), Rio de Janeiro, Brazil.,State Institute of the Brain Paulo Niemeyer, Rio de Janeiro, Brazil
| | - Mona das N Oliveira
- Department Of Biochemistry, University of São Paulo, São Paulo, São Paulo, Brazil
| | - Henning Ulrich
- Department Of Biochemistry, University of São Paulo, São Paulo, São Paulo, Brazil
| | - Giselle P de Faria Lopes
- Department of Marine Biotechnology, Institute of Sea Studies Admiral Paulo Moreira (IEAPM), Rio de Janeiro and Research Coordination, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Silvia L Costa
- Department of Biochemistry and Biophysics, Laboratory of Neurochemistry and Cell Biology, Federal University of Bahia, Salvador, Bahia, Brazil.,INCT/CNPq-Neurociência Translacional (INNT), Rio de Janeiro, Brazil
| |
Collapse
|
6
|
Yang T, Zang DW, Shan W, Guo AC, Wu JP, Wang YJ, Wang Q. Synthesis and Evaluations of Novel Apocynin Derivatives as Anti-Glioma Agents. Front Pharmacol 2019; 10:951. [PMID: 31551769 PMCID: PMC6733959 DOI: 10.3389/fphar.2019.00951] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 07/25/2019] [Indexed: 01/15/2023] Open
Abstract
Apocynin (4-hydroxy-3-methoxyacetophenone) is a natural polyphenolic compound with multiple biological activities. In the present study, a series of apocynin derivatives were designed and synthesized. The in silico ADMET prediction, blood–brain barrier (BBB) penetration assay, anti-NADPH oxidase activity, reactive oxygen species (ROS) levels, and anti-glioma effects of these apocynin derivatives were evaluated. The anti-glioma mechanisms of candidate compounds were studied by flow cytometer and Western blot. The results showed that D31 exhibited higher BBB penetration, increased ROS generations and significant anti-glioma effects both in vitro and in vivo. Further studies showed that D31 inhibited the activations of NF-κB pathway. Overall, our data demonstrated that D31 inhibited growth and induced apoptosis of glioma, which might be caused by ROS-related NF-κB activation. The current study suggested that D31 could be further explored for its potential use in anti-glioma therapy.
Collapse
Affiliation(s)
- Tao Yang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - Da-Wei Zang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - Wei Shan
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - An-Chen Guo
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - Jian-Ping Wu
- China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
| | - Yong-Jun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.,Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
| | - Qun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Centre for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| |
Collapse
|
7
|
Sun Z, Zhang Y, Cao D, Wang X, Yan X, Li H, Huang L, Qu X, Kong C, Qin H, Wang M, Xu W, Liang L. PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer. Drug Deliv 2018; 25:1746-1755. [PMID: 30394118 PMCID: PMC6225483 DOI: 10.1080/10717544.2018.1509907] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 07/03/2018] [Accepted: 08/06/2018] [Indexed: 12/14/2022] Open
Abstract
Although the cancer immunotherapy represents one of the most promising strategies for cancer treatment, the PD-1/PD-L1 pathway, which involves a receptor-ligand interaction, can induced immunosuppression by disabling tumor-infiltrating lymphocytes (TILs). In the present study, we coupled a PD-L1 (Programmed cell death 1 ligand 1) recognizable peptide DPPA-1 to the sequence of CGKRK, a namely tumor vasculature affinity peptide, to form a new molecule CD peptide. Thereafter, the paclitaxel (PTX)-loaded PCL nanoparticles were developed and modified with the above newly synthesized CD molecules for tumor cells and angiogenesis dual targeting drug delivery. Results of cellular experiments showed that the prepared nanoparticles have a high affinity to both tumor vasculature endothelial cells and tumor cells, which leads to an improved cytotoxicity to cancer cells and inhibition for angiogenesis. In addition, results of in vivo imaging assay exhibited a super tumor targeting efficacy for the CD peptide decorated nanoplatforms. Finally, the pharmacodynamic evaluation was performed and results shown that the tumor-bearing mice treated with CD-NP-PTX achieved the longest medium survival time when compared with others. Simultaneously, different nanoparticles un-loaded with drugs were also subjected to anti-tumor effect studies. Results demonstrated that the mice administrated with D-NP displayed a significantly higher ability of tumor growth inhibition when compared with the NP or C-NP, indicating a super blocking effect of PD-1/PD-L1 pathway for the DPPA-1 peptide. Collectively, these results indicated that the fabricated CD-NP-PTX holds great potential in improving the tumor-targeting drug delivery efficacy and anti-glioma effect.
Collapse
Affiliation(s)
- Zhenliang Sun
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
- Shanghai University of Medicine and Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China
| | - Yang Zhang
- Department of Pharmacy, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Duo Cao
- The College of Life Sciences, Northwest University, Xi’an, China
| | - Xufeng Wang
- Haiwan Community Health Center, Shanghai, China
| | - Xuebing Yan
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Hao Li
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Linsheng Huang
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Xiao Qu
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Cheng Kong
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Huanglong Qin
- Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
| | - Man Wang
- Shanghai University of Medicine and Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China
| | - Wei Xu
- Department of Orthopaedic, Tong Ren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Lin Liang
- Shanghai University of Medicine and Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China
| |
Collapse
|
8
|
Sun Z, Yan X, Liu Y, Huang L, Kong C, Qu X, Wang M, Gao R, Qin H. Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin. Oncotarget 2017; 8:58823-34. [PMID: 28938600 DOI: 10.18632/oncotarget.19221] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Accepted: 06/17/2017] [Indexed: 12/21/2022] Open
Abstract
Chemotherapy of glioma is always hampered by the unsatisfactory tumor accumulation of drugs, of which the most noticeable obstacle is the limited drug permeability from vessels into tumor inner. In the present study, we developed a novel nanocarrier for the delivery of doxorubicin to brain tumor. Such novel drug delivery system was mainly composed of a tumor homing peptide and DOX-loaded PLA nanoparticles (AP1-NP-DOX). CRKRLDRNC peptide, named as AP1, was a newly glioma affinity peptide which could specifically binds to interleukin-4 receptor (IL-4R), highly expressing on both glioma cells and angiogenesis. Our findings showed that the peptide-functionalized nanoparticles had a high affinity with both tumor cells and vascular endothelial cells. Besides, tumor targeting assay exhibited that AP1 decorated nanoparticles accumulated more in tumor site than the unmodified ones. Moreover, the results of tumor uptake experiments indicated that AP1-NP-DOX might own the ability of blood brain barrier (BBB) penetration. In the anti-glioma study, AP1-NP-DOX exhibited the highest therapeutic effect on tumor-bearing mice compared with the unmodified nanoparticles and free doxorubicin. These results together indicated that AP1-functionalized nanoparticles could represent a promising way to expand the treatment horizons of onco-therapy.
Collapse
|